Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Net Income: 2020-2023

Historic Net Income for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to -$15.5 million.

  • Immuneering's Net Income fell 15.44% to -$15.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$54.8 million, marking a year-over-year decrease of 8.03%. This contributed to the annual value of -$54.8 million for FY2023, which is 8.50% down from last year.
  • Immuneering's Net Income amounted to -$15.5 million in Q4 2023, which was down 18.95% from -$13.1 million recorded in Q3 2023.
  • Over the past 5 years, Immuneering's Net Income peaked at -$3.2 million during Q2 2020, and registered a low of -$15.5 million during Q4 2023.
  • Over the past 3 years, Immuneering's median Net Income value was -$12.6 million (recorded in 2022), while the average stood at -$11.6 million.
  • Data for Immuneering's Net Income shows a maximum YoY plummeted of 149.56% (in 2021) over the last 5 years.
  • Quarterly analysis of 4 years shows Immuneering's Net Income stood at -$5.8 million in 2020, then plummeted by 88.02% to -$11.0 million in 2021, then dropped by 22.75% to -$13.5 million in 2022, then decreased by 15.44% to -$15.5 million in 2023.
  • Its Net Income was -$15.5 million in Q4 2023, compared to -$13.1 million in Q3 2023 and -$12.3 million in Q2 2023.